|Articles|May 8, 2013

Orally Disintegrating Technology Provides Both Formulating Challenges and Opportunities

Drug manufacturers today are increasingly challenged to find new, effective methods for the delivery of active pharmaceutical ingredients, and many are discovering that orally disintegrating technologies can help.

Nick Johnson, strategic marketing director for modified-release technologies at Catalent Pharma Solutions, spoke with Cynthia Challener, editor of the Pharmaceutical Sciences, Manufacturing & Marketplace Report, about orally disintegrating tablets and other technologies. The editorial podcast is here.

In Part One, Nick Johnson talks about the formulating challenges presented by orally disintegrating technologies.

In Part Two, Nick Johnson discusses current effective technologies for addressing the challenges of formulating orally disintregrating products.

In Part Three, Nick Johnson highlights some of the main drivers for the development of new orally disintegrating technologies.

In Part Four, Nick Johnson describes new technologies for orally disintegrating products that are under development in response to these market needs, including projects underway at Catalent Pharma Solutions.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.